Sacubitril/Valsartan Cannot Improve Cardiac Function Compared with Valsartan in Patients Suffering Nonvalvular Atrial Fibrillation without Systolic Heart Failure-Reference-Cited by-同舟云学术

Sacubitril/Valsartan Cannot Improve Cardiac Function Compared with Valsartan in Patients Suffering Nonvalvular Atrial Fibrillation without Systolic Heart Failure

Published:2023-11-30 Issue:6 Volume:64 Page:1032-1039
ISSN:1349-2365
Container-title:International Heart Journal
language:en
Short-container-title:Int. Heart J.

Author:

Zhu Mingxin¹,Guo Jianfeng²,Qiqike Badeng³,Nay Xeri³,Dan Shan⁴,Kuransi Aidina³,Hu Gaokai³,Han Zhangtong³,Hou Dong³,Aili Ailifeilai³,Xia Bin³,Chen Ping³,Bate Bayin³,Xie Jiangjiao⁵

Affiliation:

1. Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

2. Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

3. Department of Cardiology, People's Hospital, Mongol Autonomous Prefecture of Bortala

4. Department of Ultrasonography, People's Hospital, Mongol Autonomous Prefecture of Bortala

5. Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Publisher

International Heart Journal (Japanese Heart Journal)

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/ihj/64/6/64_23-220/_pdf

Reference21 articles.

1. 1. Naser N, Dilic M, Durak A, et al. The impact of risk factors and comorbidities on the incidence of atrial fibrillation. Mater Sociomed 2017; 29: 231-6.

2. 2. Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J 2016; 37: 3232-45.

3. 3. Sartipy U, Dahlström U, Fu M, Lund LH. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail 2017; 5: 565-74.

4. 4. Voors AA, Dorhout B, van der Meer P. The potential role of valsartan + ahu377 (lcz696) in the treatment of heart failure. Expert Opin Investig Drugs 2013; 22: 1041-7.

5. 5. De Vecchis R, Paccone A, Di Maio M. Upstream therapy for atrial fibrillation prevention: the role of Sacubitril/Valsartan. Cardiol Res 2020; 11: 213-8.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Benefits of sacubitril/valsartan administration and physical training in cardiac rehabilitation: current trends and bibliometric analysis of the years 2015-2024;Balneo and PRM Research Journal;2024-06-21